Vietnam is rapidly establishing itself as one of Southeast Asia's most attractive destinations for outsourced pharmaceutical research, with growing demand for Contract Research Organization (CRO) services driven by increased clinical trial activity, pharmaceutical investment and biotechnology innovation.
While there is currently no dedicated published valuation for Vietnam's CRO services market, industry analysis indicates the sector is worth an estimated US$240–300 million in 2025 and could expand to US$430–550 million by 2030. The market is being fuelled by rising pharmaceutical R&D investment, greater participation in multinational clinical trials and increasing demand for specialist outsourced research services.
Contract Research Organizations play an essential role in modern drug development by providing outsourced scientific, regulatory and operational expertise to pharmaceutical, biotechnology and medical device companies. As drug development becomes increasingly complex and costly, sponsors are relying more heavily on CROs to improve efficiency, reduce timelines and accelerate product approvals.
The market includes a broad range of specialist services, including:
- Clinical trial management
- Pre-clinical research
- Site management and patient recruitment
- Regulatory affairs
- Medical writing
- Biostatistics and data management
- Pharmacovigilance
- Biomarker development
- Real-world evidence studies
- Medical device clinical evaluations
Vietnam offers several competitive advantages that are attracting international sponsors. A population of more than 100 million people, a growing burden of chronic diseases, improving hospital infrastructure and an expanding network of research institutions provide access to diverse patient populations for clinical studies. Combined with competitive operating costs and an increasingly skilled scientific workforce, Vietnam is becoming an attractive destination for regional and global clinical development programmes.
Growth in domestic pharmaceutical manufacturing is also increasing demand for CRO services. As Vietnamese pharmaceutical companies expand research activities, develop biosimilars and pursue more sophisticated therapies, they are increasingly outsourcing specialist capabilities such as clinical operations, regulatory submissions, pharmacovigilance and medical data management. International pharmaceutical companies are similarly expanding their clinical development programmes across Southeast Asia, creating further opportunities for local and regional CRO providers.
Technology is reshaping the CRO industry worldwide. Artificial intelligence is improving protocol design, patient recruitment and clinical data analysis, while decentralised clinical trials (DCTs), remote monitoring, electronic data capture (EDC) and digital patient engagement platforms are enabling faster, more efficient research. These innovations are expected to play an increasingly important role as Vietnam's clinical research ecosystem continues to mature.
The wider Asia-Pacific region continues to outperform many global markets. According to Market Data Forecast, the Asia-Pacific CRO services market is projected to grow from US$7.32 billion to more than US$15 billion by 2033, reflecting strong demand for outsourced research across the region. Vietnam is well positioned to benefit from this momentum as pharmaceutical companies diversify clinical development programmes beyond traditional research hubs.
Globally, the CRO services market is experiencing sustained expansion. IMARC Group estimates the global market reached US$83.6 billion in 2025 and will grow to US$169.8 billion by 2034, while MarketsandMarkets forecasts continued growth driven by increasingly complex clinical trials, biologics, personalised medicine and greater outsourcing across the pharmaceutical industry.
Leading international CROs include IQVIA, ICON plc, Parexel, Fortrea, PPD (Thermo Fisher Scientific), Charles River Laboratories, Medpace, Syneos Health, WuXi AppTec and Labcorp Drug Development. These organisations continue to invest in AI-enabled clinical research, decentralised trials, real-world evidence and integrated development services to support pharmaceutical innovation worldwide.
As Vietnam continues to strengthen its pharmaceutical industry, modernise healthcare infrastructure and attract international investment in life sciences, demand for outsourced research services is expected to accelerate. For CROs, pharmaceutical companies, biotechnology firms, medical device manufacturers, clinical technology providers and research institutions, Vietnam represents one of Southeast Asia's most promising emerging markets for clinical development and contract research.
